Cargando…

Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

This review will focus on recent advances in the application of antiepidermal growth factor receptor (anti-EGFR) for the treatment of breast cancer. The choice of EGFR, a member of the ErbB tyrosine kinase receptor family, stems from evidence pinpointing its role in various anti-EGFR therapies. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flynn, John F., Wong, Christina, Wu, Joseph M.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668926/ https://www.ncbi.nlm.nih.gov/pubmed/19390622 http://dx.doi.org/10.1155/2009/526963

Ejemplares similares

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
por: Harandi, Amir, et al.
Publicado: (2009)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru
por: Galvez‐Nino, Marco, et al.
Publicado: (2022)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Update on Anti-EGFR Therapy
por: Chua, Daniel, et al.
Publicado: (2009)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer
por: Knebel, Franciele H., et al.
Publicado: (2019)

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Unexpected insights for anti-EGFR cancer therapy
por: Depeille, Philippe, et al.
Publicado: (2015)

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
por: Bai, Ming, et al.
Publicado: (2022)

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
por: Li, Qing-Hai, et al.
Publicado: (2020)

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
por: Zhou, Jing, et al.
Publicado: (2021)

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone
por: ten Hoorn, Sanne, et al.
Publicado: (2021)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
por: Maity, Swastika, et al.
Publicado: (2020)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
por: Thomas, Brian J., et al.
Publicado: (2023)

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2018)

Anti‐EGFR Therapy in Small Bowel Adenocarcinoma
por: Safyan, Rachael A., et al.
Publicado: (2018)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
por: Kasper, Stefan, et al.
Publicado: (2017)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
por: Tsai, Ming-Ju, et al.
Publicado: (2023)

Near-infrared photothermal therapy using anti-EGFR-gold nanorod conjugates for triple negative breast cancer
por: Zhang, Meihua, et al.
Publicado: (2017)

Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies
por: Roncato, Francesco, et al.
Publicado: (2018)

Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism
por: Hsu, Chih-Neng, et al.
Publicado: (2023)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
por: Mamot, Christoph, et al.
Publicado: (2023)

Heterogeneous EGFR Gene Copy Number Increase Is Common in Colorectal Cancer and Defines Response to Anti-EGFR Therapy
por: Ålgars, Annika, et al.
Publicado: (2014)

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
por: Hoshi, Hirotaka, et al.
Publicado: (2017)

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
por: Huang, Chu-Ying, et al.
Publicado: (2015)

Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept
por: Dragovich, Tomislav, et al.
Publicado: (2009)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2db7dlohpqgf17t3p6jdb14uqp